Results

AMN Healthcare Services Inc.

03/25/2025 | Press release | Archived content

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
AMN Healthcare Services Inc. published this content on March 25, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 03, 2025 at 05:39 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]